Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06023095
PHASE1

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.

Official title: A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2023-09-21

Completion Date

2024-07-29

Last Updated

2026-07-17

Healthy Volunteers

No

Interventions

DRUG

LY3502970

Administered orally.

DRUG

Placebo

Administered orally.

Locations (3)

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

West China Hospital Sichuan University

Chengdu, Sichuan, China

Shanghai General Hospital

Shanghai, Songjiang, China